(0.22%) 5 143.00 points
(0.18%) 38 510 points
(0.32%) 17 903 points
(-0.36%) $83.55
(1.92%) $1.960
(0.11%) $2 349.70
(0.56%) $27.69
(0.95%) $930.90
(-0.12%) $0.934
(-0.24%) $11.00
(-0.23%) $0.799
(1.18%) $92.96
Live Chart Being Loaded With Signals
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology...
Stats | |
---|---|
Šios dienos apimtis | 1.40M |
Vidutinė apimtis | 1.57M |
Rinkos kapitalizacija | 44.87M |
EPS | $0 ( 2024-03-27 ) |
Kita pelno data | ( $-0.0300 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.630 |
ATR14 | $0 (0.00%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-12-15 | Matkovits Theresa | Buy | 1 300 000 | Stock Option (right to Buy) |
2023-12-15 | Hoover Thomas | Buy | 1 000 000 | Stock Option (right to Buy) |
2023-12-15 | Kucinski Keith A | Buy | 1 000 000 | Stock Option (right to Buy) |
2023-12-15 | Liu Hui | Buy | 1 000 000 | Stock Option (right to Buy) |
2023-12-15 | Jabbour Jerome D | Buy | 3 500 000 | Stock Option (right to Buy) |
INSIDER POWER |
---|
97.71 |
Last 97 transactions |
Buy: 33 257 124 | Sell: 4 123 116 |
Tūris Koreliacija
Matinas BioPharma Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Matinas BioPharma Koreliacija - Valiuta/Žaliavos
Matinas BioPharma Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $1.10M |
Bruto pelnas: | $155 000 (14.14 %) |
EPS: | $-0.110 |
FY | 2023 |
Pajamos: | $1.10M |
Bruto pelnas: | $155 000 (14.14 %) |
EPS: | $-0.110 |
FY | 2022 |
Pajamos: | $3.19M |
Bruto pelnas: | $-13.49M (-423.15 %) |
EPS: | $-0.0600 |
FY | 2021 |
Pajamos: | $33.00 |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-0.110 |
Financial Reports:
No articles found.
Matinas BioPharma
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 free fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Allergy and Infectious Diseases for the development of Gilead's antiviral remdesivir; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. The company was incorporated in 2013 and is based in Bedminster, New Jersey.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.